Last reviewed · How we verify
VXA-G1.1-NN
At a glance
| Generic name | VXA-G1.1-NN |
|---|---|
| Also known as | GI.1 oral vaccine tablet, GI.1, Oral Tableted Ad5 Norovirus GI.1 Vaccine |
| Sponsor | Vaxart |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate Vaxart's Oral Bivalent GI.1/GII.4 Norovirus Vaccine in Healthy Lactating Females and Their Nursing Infants (PHASE1)
- Norovirus Challenge Study (PHASE1, PHASE2)
- A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ 80 Years Old (PHASE1)
- A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers (PHASE2)
- A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult Volunteers (PHASE1)
- Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus Vaccines (PHASE1, PHASE2)
- Safety & Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines (PHASE1)
- Phase 1 Placebo-controlled, Randomized Trial of an Adenoviral-vector Based Norovirus Vaccine (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VXA-G1.1-NN CI brief — competitive landscape report
- VXA-G1.1-NN updates RSS · CI watch RSS
- Vaxart portfolio CI